But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Amyloid plaques are areas where amyloid (again ... As such, these medications come with the risk of brain bleeding, brain swelling, and brain shrinkage, making them risky to use, Dr. Segil ...

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

The European Medicines Agency committee declined to approve Eli Lilly's Alzheimer’s treatment, citing risks of brain bleeding ...